ClinicalTrials.gg
CompletedNCT04834414CHIPSUpdated Nov 16, 2026Results posted

CHIlled Platelet Study "CHIPS"

A Phase 3 interventional study of Cold Stored Platelets and Room Temperature Platelets in Acute Blood Loss, sponsored by Philip Spinella. Completed at 27 sites in 2 countries. Open to participants aged 0 Days to 84 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Philip Spinella · Phase 3, Interventional, and Treatment

How we know

Updated Nov 16, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
0 Days to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 356 studies in Hemorrhage with a site in United States — 55 open to participants now, 74 under way, 14 of them phase 3. Hemorrhage · United States.

Enrollment
20th of 257
1,000 · median 68
Started
2021
with 15 others
Phase 3
47 of 356
11 open now
Registered
264th of 356
by date

Among the 356 studies in Hemorrhage with a site in United States, this one is the 20th largest by enrollment of the 257 interventional ones that give a count, is one of 16 that started in 2021, is one of 47 in phase 3, and was the 264th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

55 of the 356 studies in Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 0 Days to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.

03

Conditions studied

  • Acute Blood Loss

Browse trials for

Keywords

  • platelets
  • cold-stored platelets
  • bleeding
  • hemostasis
  • complex cardiac surgery
04

Who can participate

Ages eligible
0 Days to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
  • Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring transfusion.

Exclusion criteria

Exclusion Criteria:

  • Expected order for washed or volume reduced
  • Patient with known anti-platelet antibodies
  • Platelet transfusion refractoriness due to anti-HLA antibodies
  • Known or suspected pregnancy
  • Previously randomized in this study
  • Conscious objection or unwillingness to receive blood products
  • Known IgA deficiency
  • Known congenital platelet disorder
  • Known congenital bleeding disorder
  • Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
  • Patients intended to receive whole blood either intra-operative or post-operative for bleeding
  • Platelet transfusion (of any type) within 24 hours prior to the date of surgery
  • Pre-operative thrombocytopenia, defined as platelet count \<75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,000 participants (actual)

Study arms

  • Active comparator
    Room Temperature Platelets

    Platelets stored at 20-24 degrees Celsius

    Biological: Room Temperature Platelets

  • Experimental
    Cold Stored Platelets

    Platelets stored at 1-6 degree Celsius

    Biological: Cold Stored Platelets

Interventions

  • BiologicalCold Stored Platelets

    Platelets stored at 1-6 degree Celsius

  • BiologicalRoom Temperature Platelets

    Platelets stored at 20-24 degrees Celsius

06

What researchers measure

Primary outcomes

  1. Hemostatic Efficacy

    Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.

    Time frame: 24 hours after first study platelet transfusion

Secondary outcomes

  1. Chest Tube Output Through 24 Hours

    Chest tube output will be assessed by volume

    Time frame: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Other outcomes

  1. Blood Product Administration

    The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood

    Time frame: 24 and 72 hours from start time of first study platelet transfusion

  2. Transfusion Associated Adverse Events

    As per CDC guidelines for transfusion associated adverse events

    Time frame: within 7 days of first study platelet transfusion

  3. Arterial Thrombotic Event

    Stroke, MI, aortic thromboic even

    Time frame: within 7 days of first study platelet transfusion

  4. Venous Thrombotic Event

    Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram

    Time frame: within 7 days of first study platelet transfusion

  5. All Cause Mortality

    Death for any reason

    Time frame: up to 28 days

  6. Total Dose of Individual Hemostatic Adjuncts (Units/kg)

    Antifibrinolytic and coagulation factor concentrates

    Time frame: 24 and 72 hours from start time of first study platelet transfusion

  7. Total Dose of Individual Hemostatic Adjuncts (mcg/kg)

    Antifibrinolytic and coagulation factor concentrates

    Time frame: 24 and 72 hours from start time of first study platelet transfusion

  8. Total Dose of Individual Hemostatic Adjuncts (mg/kg)

    Antifibrinolytic and coagulation factor concentrates

    Time frame: 24 and 72 hours from start time of first study platelet transfusion

  9. Total Dose of Individual Hemostatic Adjuncts (Grams/kg)

    Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid

    Time frame: 24 and 72 hours from start time of first study platelet transfusion

  10. Mechanical Ventilation

    Number of participants with need for mechanical ventilation

    Time frame: up to 28 days after first study platelet transfusion

  11. Length of Stay

    ICU and hospital length of stay

    Time frame: up to 28 days

  12. Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin

    Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

    Time frame: 6 and 24 hours after first study platelet transfusion

  13. Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit

    Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).

    Time frame: 6 and 24 hours after first study platelet transfusion

  14. Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count

    Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

    Time frame: 6 and 24 hours after first study platelet transfusion

  15. Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR

    Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

    Time frame: 6 and 24 hours after first study platelet transfusion

  16. Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT

    Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

    Time frame: 6 and 24 hours after first study platelet transfusion

  17. Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen

    Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

    Time frame: 6 and 24 hours after first study platelet transfusion

  18. Unplanned Sternal Closure Delay

    Sternum left open after cardiac surgery

    Time frame: prior to ICU admission

  19. Re-exploration for Bleeding

    Return to OR after ICU admission

    Time frame: 24 hours first study platelet transfusion

  20. Unplanned Extracorporeal Support Post Operatively

    Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion

    Time frame: within 48 hours of first study platelet transfusion

  21. Morbidities After ICU Admission

    Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock

    Time frame: within 7 days of first study platelet transfusion

  22. Measures of End Organ Injury- BUN and Creatinine

    If BUN, creatinine are collected clinically.- worst value

    Time frame: within 48 hours of first study platelet transfusion worst value

  23. Measures of End Organ Injury- Lactate

    If lactate was collected clinically. Worst value

    Time frame: within 48 hours of first study platelet transfusion worst value

  24. Measures of End Organ Injury- Troponin

    If lactate was collected clinically. Worst value

    Time frame: within 48 hours of first study platelet transfusion.

  25. Measures of End Organ Injury- ALT and AST

    If lactate was collected clinically. Worst value

    Time frame: within 48 hours of first study platelet transfusion.

07

Results

Posted Nov 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneRoom Temperature PlateletsCold Stored Platelets
Started340660
Completed334637
Not completed623

Outcome measures

PrimaryHemostatic Efficacy

Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.

Time frame:
24 hours after first study platelet transfusion
Reported as:
Mean · Perioperative Bleeding score
Hemostatic Efficacy
Perioperative Bleeding scoreRoom Temperature PlateletsCold Stored Platelets
Hemostatic Efficacy3.0 ± 1.13.1 ± 1.2
SecondaryChest Tube Output Through 24 Hours

Chest tube output will be assessed by volume

Time frame:
24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
Reported as:
Mean · mL/kg
Chest Tube Output Through 24 Hours
mL/kgRoom Temperature PlateletsCold Stored Platelets
Chest Tube Output Through 24 Hours12.8 ± 1213.9 ± 16.4
Other pre-specifiedBlood Product Administration

The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood

Time frame:
24 and 72 hours from start time of first study platelet transfusion
Reported as:
Mean · mL/kg
Blood Product Administration
mL/kgRoom Temperature Platelets Within 24 Hours of First Platelet TransfusionCold Stored Platelets Within 24 Hours of the First Platelet TransfusionRoom Temperature Platelets Within 72 Hours of First Platelet TransfusionCold Stored Platelets Within 72 Hours of the First Platelet Transfusion
RBC4.2 ± 9.46.2 ± 16.121.5 ± 23.029.0 ± 43.3
Plasma2.8 ± 4.64.6 ± 12.25.3 ± 11.07.6 ± 18.5
Platelets10.8 ± 9.313.5 ± 14.311.3 ± 10.014.6 ± 16.9
Cryoprecipitate1.7 ± 2.51.7 ± 2.51.7 ± 2.61.7 ± 2.5
Whole blood0.1 ± 0.70.3 ± 2.70.1 ± 0.70.3 ± 2.7
Other pre-specifiedTransfusion Associated Adverse Events

As per CDC guidelines for transfusion associated adverse events

Time frame:
within 7 days of first study platelet transfusion
Reported as:
Count of participants · Participants
Transfusion Associated Adverse Events
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Transfusion Associated Adverse Events01
Other pre-specifiedArterial Thrombotic Event

Stroke, MI, aortic thromboic even

Time frame:
within 7 days of first study platelet transfusion
Reported as:
Count of participants · Participants
Arterial Thrombotic Event
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Stroke1110
MI03
Aortic Thrombotic Event25
No Arterial Thrombotic Event327642
Other pre-specifiedVenous Thrombotic Event

Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram

Time frame:
within 7 days of first study platelet transfusion
Reported as:
Count of participants · Participants
Venous Thrombotic Event
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Pulmonary embolism23
Deep Vein Thrombosis49
Catheter associated thrombotic event26
No venous thrombotic events332642
Other pre-specifiedAll Cause Mortality

Death for any reason

Time frame:
up to 28 days
Reported as:
Count of participants · Participants
All Cause Mortality
ParticipantsRoom Temperature PlateletsCold Stored Platelets
All Cause Mortality621
Other pre-specifiedTotal Dose of Individual Hemostatic Adjuncts (Units/kg)

Antifibrinolytic and coagulation factor concentrates

Time frame:
24 and 72 hours from start time of first study platelet transfusion
Reported as:
Mean · units/kg
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
units/kgRoom Temperature Platelets Within 24 Hours of First Platelet TransfusionCold Stored Platelets Within 24 Hours of First Platelet TransfusionRoom Temperature Platelets Within 72 Hours of First Platelet TransfusionCold Stored Platelets Within 72 Hours of First Platelet Transfusion
Anit-inhibitor coagulant complex (units/kg)0.3 ± 1.80.2 ± 1.70.3 ± 1.80.2 ± 1.7
Prothrombin complex concentrate (3 factor) (units/kg)0.2 ± 2.30.4 ± 3.50.2 ± 2.30.4 ± 3.5
3Prothrombin complex concentrate (factor 4) (units/kg)3.9 ± 18.63.8 ± 11.43.9 ± 18.63.9 ± 11.5
Other pre-specifiedTotal Dose of Individual Hemostatic Adjuncts (mcg/kg)

Antifibrinolytic and coagulation factor concentrates

Time frame:
24 and 72 hours from start time of first study platelet transfusion
Reported as:
Mean · mcg/kg
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
mcg/kgRoom Temperature Platelets Within 24 Hours of First Platelet TransfusionCold Stored Platelets Within 24 Hours of First Platelet TransfusionRoom Temperature Platelets Within 72 Hours of First Platelet TransfusionCold Stored Platelets Within 72 Hours of First Platelet Transfusion
DDAVP (mcg/kg)0.0 ± 0.10.0 ± 0.10.0 ± 0.10.0 ± 0.1
Recombinant factor VIIa (rFVIIa) (mcg/kg)8.0 ± 32.913.2 ± 121.82.8 ± 23.913.5 ± 122.2
Other pre-specifiedTotal Dose of Individual Hemostatic Adjuncts (mg/kg)

Antifibrinolytic and coagulation factor concentrates

Time frame:
24 and 72 hours from start time of first study platelet transfusion
Reported as:
Mean · mg/kg
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
mg/kgRoom Temperature Platelets Within 24 Hours of First Platelet TransfusionCold Stored Platelets Within 24 Hours of First Platelet TransfusionRoom Temperature Platelets Within 72 Hours of First Platelet TransfusionCold Stored Platelets Within 72 Hours of First Platelet Transfusion
Antithrobim III (mg/kg)0.0 ± 0.90.0 ± 0.00.0 ± 0.90.0 ± 0.0
Factor XIII concentrate (mg/kg)0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Factor concentrate other (mg/kg)0.1 ± 2.70.0 ± 0.00.1 ± 2.70.0 ± 0.0
Tranexamic acid (mg/kg)1.7 ± 10.11.6 ± 8.91.7 ± 10.11.6 ± 8.9
Other pre-specifiedTotal Dose of Individual Hemostatic Adjuncts (Grams/kg)

Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid

Time frame:
24 and 72 hours from start time of first study platelet transfusion
Reported as:
Mean · grams/kg
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
grams/kgRoom Temperature Platelets Within 24 Hours of First Platelet TransfusionCold Stored Platelets Within 24 Hours of First Platelet TransfusionRoom Temperature Platelets Within 72 Hours of First Platelet TransfusionCold Stored Platelets Within 72 Hours of First Platelet Transfusion
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Other pre-specifiedMechanical Ventilation

Number of participants with need for mechanical ventilation

Time frame:
up to 28 days after first study platelet transfusion
Reported as:
Count of participants · Participants
Mechanical Ventilation
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Mechanical Ventilation283552
Other pre-specifiedLength of Stay

ICU and hospital length of stay

Time frame:
up to 28 days
Reported as:
Mean · days
Length of Stay
daysRoom Temperature PlateletsCold Stored PlateletsMixed
Length of Stay5.8 ± 5.85.0 ± 4.810.4 ± 8.7
Other pre-specifiedRelative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

Time frame:
6 and 24 hours after first study platelet transfusion
Reported as:
Mean · unitless ratio
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
unitless ratioRoom Temperature Platelets 6 Hours Post TransfusionCold Stored Platelets 6 Hours Post TransfusionRoom Temperature Platelets 24 Hours Post TransfusionCold Stored Platelets 24 Hours Post Transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin0.61 ± 1.970.67 ± 1.97-0.13 ± 1.83-0.02 ± 1.91
Other pre-specifiedRelative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).

Time frame:
6 and 24 hours after first study platelet transfusion
Reported as:
Mean · unitless ratio
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
unitless ratioRoom Temperature Platelets 6 Hours Post TransfusionCold Stored Platelets 6 Hours Post TransfusionRoom Temperature Platelets 24 Hours Post TransufusionCold Stored Platelets 24 Hours Post Transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit0.07 ± 0.190.09 ± 0.200.00 ± 0.170.02 ± 0.17
Other pre-specifiedRelative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

Time frame:
6 and 24 hours after first study platelet transfusion
Reported as:
Mean · unitless ratio
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
unitless ratioRoom Temperature Platelets 6 Hours Post TransfusionCold Stored Platelets 6 Hours Post TransfusionRoom Temperature Platelets 24 Hours Post TransfusionCold Store Platelets 24 Hours Post Transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count0.91 ± 1.120.17 ± 0.440.60 ± 0.970.08 ± 0.47
Other pre-specifiedRelative Change in Hemostatic Parameters at 6 and 24 Hours- INR

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

Time frame:
6 and 24 hours after first study platelet transfusion
Reported as:
Mean · unitless
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
unitlessRoom Temperature Platelets 6 Hours Post TransfusionCold Stored Platelets 6 Hours Post TransfusionRoom Temperature Platelets 24 Hours Post TransfusionCold Store Platelets 24 Hours Post Transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR-0.25 ± 0.16-0.24 ± 0.15-0.18 ± 0.17-0.18 ± 0.19
Other pre-specifiedRelative Change in Hemostatic Parameters at 6 and 24 Hours- PTT

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

Time frame:
6 and 24 hours after first study platelet transfusion
Reported as:
Mean · unitless ratio
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
unitless ratioRoom Temperature Platelets 6 Hours Post TransfusionCold Stored Platelets 6 Hours Post TransfusionRoom Temperature Platelets 24 Hours Post TransfusionCold Store Platelets 24 Hours Post Transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT-0.17 ± 0.41-0.12 ± 0.44-0.20 ± 0.46-0.16 ± 0.53
Other pre-specifiedRelative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

Time frame:
6 and 24 hours after first study platelet transfusion
Reported as:
Mean · unitless ratio
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
unitless ratioRoom Temperature Platelets 6 Hours Post TransfusionCold Stored Platelets 6 Hours Post TransfusionRoom Temperature Platelets 24 Hours Post TransfusionCold Store Platelets 24 Hours Post Transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen0.46 ± 0.430.44 ± 0.471.01 ± 0.661.04 ± 0.66
Other pre-specifiedUnplanned Sternal Closure Delay

Sternum left open after cardiac surgery

Time frame:
prior to ICU admission
Reported as:
Count of participants · Participants
Unplanned Sternal Closure Delay
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Unplanned Sternal Closure Delay520
Other pre-specifiedRe-exploration for Bleeding

Return to OR after ICU admission

Time frame:
24 hours first study platelet transfusion
Reported as:
Count of participants · Participants
Re-exploration for Bleeding
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Re-exploration for Bleeding628
Other pre-specifiedUnplanned Extracorporeal Support Post Operatively

Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion

Time frame:
within 48 hours of first study platelet transfusion
Reported as:
Count of participants · Participants
Unplanned Extracorporeal Support Post Operatively
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Unplanned Extracorporeal Support Post Operatively1125
Other pre-specifiedMorbidities After ICU Admission

Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock

Time frame:
within 7 days of first study platelet transfusion
Reported as:
Count of participants · Participants
Morbidities After ICU Admission
ParticipantsRoom Temperature PlateletsCold Stored Platelets
Acute respiratory distress syndrome820
Need for renal support1727
Renal failure2341
Septic Shock37
No morbidities289565
Other pre-specifiedMeasures of End Organ Injury- BUN and Creatinine

If BUN, creatinine are collected clinically.- worst value

Time frame:
within 48 hours of first study platelet transfusion worst value
Reported as:
Mean · mg/dL
Measures of End Organ Injury- BUN and Creatinine
mg/dLRoom Temperature PlateletsCold Stored Platelets
BUN20.0 (16.0 to 28.0)20 (15.0 to 25.1)
Creatinine1.1 (0.7 to 1.4)1.1 (0.7 to 1.4)
Other pre-specifiedMeasures of End Organ Injury- Lactate

If lactate was collected clinically. Worst value

Time frame:
within 48 hours of first study platelet transfusion worst value
Reported as:
Mean · mmol/L
Measures of End Organ Injury- Lactate
mmol/LRoom Temperature PlateletsCold Stored Platelets
Measures of End Organ Injury- Lactate3.5 (2.0 to 6.3)3.7 (2.3 to 7.2)
Other pre-specifiedMeasures of End Organ Injury- Troponin

If lactate was collected clinically. Worst value

Time frame:
within 48 hours of first study platelet transfusion.
Reported as:
Mean · mg/mL
Measures of End Organ Injury- Troponin
mg/mLRoom Temperature PlateletsCold Stored Platelets
Measures of End Organ Injury- Troponin6.3 (4.7 to 22.1)6.3 (3.0 to 13.4)
Other pre-specifiedMeasures of End Organ Injury- ALT and AST

If lactate was collected clinically. Worst value

Time frame:
within 48 hours of first study platelet transfusion.
Reported as:
Mean · U/L
Measures of End Organ Injury- ALT and AST
U/LRoom Temperature PlateletsCold Stored Platelets
ALT24.0 (16.0 to 37.0)22.0 (16.0 to 34.0)
AST74.54 (41.5 to 112.5)75.0 (46.0 to 119.0)

Adverse events

Collected over Adverse events were collected up to 28 days after platelet transfusion. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Room Temperature Platelets6/342 (1.8%)147/342 (43%)204/342 (59.6%)
Cold Stored Platelets9/566 (1.6%)99/566 (17.5%)347/566 (61.3%)
Mixed12/92 (13%)77/92 (83.7%)77/92 (83.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRoom Temperature PlateletsCold Stored PlateletsMixed
cardiac disordersCardiac disorders37/34266/56621/92
respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders25/34241/56615/92
Infections and infestationsInfections and infestations10/34218/5669/92
Surgical and medical proceduresSurgical and medical procedures4/3426/5669/92
Vascular disordersVascular disorders14/3428/5669/92
injury, poisoning and procedural complicationsInjury, poisoning and procedural complications6/3429/5668/92
Renal and urinary disordersRenal and urinary disorders15/34212/5666/92
nervous system disordersNervous system disorders13/34214/5665/92
General disorders and administration site conditionsGeneral disorders4/34210/5664/92
Gastrointestinal disordersGastrointestinal disorders9/3429/5660/92
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRoom Temperature PlateletsCold Stored PlateletsMixed
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders74/342146/56631/92
Vascular disordersVascular disorders71/34293/56631/92
Cardiac disordersCardiac disorders55/34292/56627/92
General disorders and administarion site conditionsGeneral disorders48/34279/56619/92
Renal and urinary disordersRenal and urinary disorders38/34247/56616/92
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications12/34221/56612/92
Surgical and medical proceduresSurgical and medical procedures7/34212/56612/92
Metabolic and nutrition disordersMetabolism and nutrition disorders43/34273/5667/92
Infections and infestationsInfections and infestations17/34228/56611/92
Blood and lymphatic system disordersBlood and lymphatic system disorders20/34242/5667/92

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Room Temperature PlateletsCold Stored PlateletsTotal
Mean41.8 ± 30.442.3 ± 3042.1 ± 55.4
Sex: Female, Male
Sex: Female, Male(Participants)Room Temperature PlateletsCold Stored PlateletsTotal
Female118204322
Male222456678
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Room Temperature PlateletsCold Stored PlateletsTotal
Hispanic or Latino3881119
Not Hispanic or Latino287555842
Unknown or Not Reported152439
Region of Enrollment
Region of Enrollment(participants)Room Temperature PlateletsCold Stored PlateletsTotal
United States310616926
Australia304474
08

Study locations

27 sites
  • Mayo Clinic Arizona
    Pheonix, Arizona 85054, United States
  • Banner University Medical Center
    Tuscon, Arizona 85713, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Loyola Universtiy Medical Center
    Maywood, Illinois 60153, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66103, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • John Hopkins
    Baltimore, Maryland 21287, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Wake Forest
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02910, United States
  • University of Texas Children's Medical Center
    Dallas, Texas 75235, United States
  • University of Texas Medical Center Clements
    Dallas, Texas 75235, United States
  • Baylor Texas Children's
    Houston, Texas 77030, United States
  • Memorial Hermann Texas Medical Center
    Houston, Texas 77030, United States
  • University of Wisconsin- Madison
    Madison, Wisconsin 53792, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
09

References and documents

Publications

  • Krachey E, Viele K, Spinella PC, Steiner ME, Zantek ND, Lewis RJ. The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S41-S46. doi: 10.1097/TA.0000000000001876. PubMed 29521797 ↗
  • Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, Kristoffersen EK, Haaverstad R, Kvalheim V, Braathen H, Lunde THF, Hervig T, Hufthammer KO, Spinella PC, Apelseth TO. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex Cardiothoracic Surgery. Anesthesiology. 2020 Dec 1;133(6):1173-1183. doi: 10.1097/ALN.0000000000003550. PubMed 32902572 ↗
  • Zantek ND, Steiner ME, VanBuren JM, Lewis RJ, Berry NS, Viele K, Krachey E, Dean JM, Nelson S, Spinella PC. Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study. Clin Trials. 2023 Feb;20(1):36-46. doi: 10.1177/17407745221126423. Epub 2022 Dec 21. PubMed 36541257 ↗
  • Spinella PC, Zantek ND, VanBuren JM, Nicolson SC, Khanna AK, Klompas AM, Boisen ML, Williams TM, Monteleone M, Bashir DA, Pavey W, Smith BB, Ahmed MI, Niebler RA, Jeng E, Flynn BC, Joshi RV, Preuss JF, Goswami D, Yamada C, Lewis C, Cohn CS, Tint H, Kwak J, Sodha N, Simon ER, Van PY, Greilich PE, Booth FVM, Carter CP, Keegan A, Cap AP, Matuk J, McGlothlin A, Berry NS, Lewis RJ, Steiner ME; CHIPS Investigator Group. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026 Aug 17. doi: 10.1001/jama.2026.13328. Online ahead of print. PubMed 42606886 ↗
  • Lewis AR, Peffley N, Klompas AM, Ashrani AA. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. Transfusion. 2023 Sep;63(9):1773-1777. doi: 10.1111/trf.17477. Epub 2023 Jul 10. PubMed 37427705 ↗
  • Klompas AM, Stubbs J. Massive transfusion protocol: What's in a name? Transfusion. 2023 Apr;63(4):896-897. doi: 10.1111/trf.17297. No abstract available. PubMed 37038736 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Mar 2025, 41 months.

Results were first posted in Nov 2026, 1 year 7 months after primary completion.

Of 45 non-industry phase 3 interventional studies under Hemorrhage, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 41 months is close to that.

Counting every sponsor, half of 72 studies reached it within 42 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2021
First posted
Apr 8, 2021
StartActual
Oct 21, 2021
Primary completionActual
Mar 25, 2025
CompletionActual
Apr 21, 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Mayo Clinic Arizona · Pheonix, United States
  • Banner University Medical Center · Tuscon, United States
Show 2 removed
  • Mayo Clinic Arizona · Phoenix, United States
  • Banner University Medical Center · Tucson, United States
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedHemostatic efficacyEfficacyTime frame: 24 hours after first study platelet transfusion
Nov 16, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42606886 ↗
Nov 16, 2026
Secondary outcomes
15 edited, 11 added
What changed in the outcomes
  • EditedChest tube outputTube Output Through 24 HoursTime frame: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
  • Editedother outcomeBlood product administrationProduct AdministrationTime frame: 24 and 72 hours from start time of first study platelet transfusion
  • Editedother outcomeTotal Dose of individual hemostatic adjunctsIndividual Hemostatic Adjuncts (Units/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
  • Editedother outcomeMechanical ventilationVentilationTime frame: up to 28 days after first study platelet transfusion
  • Editedother outcomeLength of stayStayTime frame: up to 28 days
  • Editedother outcomeRelative changeChange in hemostatic parametersHemostatic Parameters at 6 and 24 Hours - HemoglobinTime frame: 6 and 24 hours after first study platelet transfusion
  • Editedother outcomeUnplanned sternal closure delaySternal Closure DelayTime frame: prior to ICU admission
  • Editedother outcomeRe-exploration for bleedingBleedingTime frame: 24 hours first study platelet transfusion
  • Editedother outcomeUnplanned extracorporeal support post operativelyExtracorporeal Support Post OperativelyTime frame: within 48 hours of first study platelet transfusion
  • Editedother outcomeMorbidities afterAfter ICU admissionAdmissionTime frame: within 7 days of first study platelet transfusion
  • Editedother outcomeMeasures of end organ injuryEnd Organ Injury- BUN and CreatinineTime frame: within 48 hours of first study platelet transfusion → within 48 hours of first study platelet transfusion worst value
  • Editedother outcomeTransfusion associated adverse eventsAssociated Adverse EventsTime frame: within 7 days of first study platelet transfusion
  • Editedother outcomeArterial thrombotic eventThrombotic EventTime frame: within 7 days of first study platelet transfusion
  • Editedother outcomeVenous thrombotic eventThrombotic EventTime frame: within 7 days of first study platelet transfusion
  • Editedother outcomeAll cause mortalityCause MortalityTime frame: up to 28 days
  • Addedother outcomeTotal Dose of Individual Hemostatic Adjuncts (mcg/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
  • Addedother outcomeTotal Dose of Individual Hemostatic Adjuncts (mg/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
  • Addedother outcomeTotal Dose of Individual Hemostatic Adjuncts (Grams/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
  • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours - HematocritTime frame: 6 and 24 hours after first study platelet transfusion
  • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet CountTime frame: 6 and 24 hours after first study platelet transfusion
  • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- INRTime frame: 6 and 24 hours after first study platelet transfusion
  • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- PTTTime frame: 6 and 24 hours after first study platelet transfusion
  • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- FibrinogenTime frame: 6 and 24 hours after first study platelet transfusion
  • Addedother outcomeMeasures of End Organ Injury- LactateTime frame: within 48 hours of first study platelet transfusion worst value
  • Addedother outcomeMeasures of End Organ Injury- TroponinTime frame: within 48 hours of first study platelet transfusion.
  • Addedother outcomeMeasures of End Organ Injury- ALT and ASTTime frame: within 48 hours of first study platelet transfusion.
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42606886 ↗
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Mayo Clinic Arizona · Pheonix, United States
    • Banner University Medical Center · Tuscon, United States
    Show 2 removed
    • Mayo Clinic Arizona · Phoenix, United States
    • Banner University Medical Center · Tucson, United States
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedHemostatic efficacyEfficacyTime frame: 24 hours after first study platelet transfusion
    Secondary outcomes 15 edited, 11 added
    What changed in the outcomes
    • EditedChest tube outputTube Output Through 24 HoursTime frame: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
    • Editedother outcomeBlood product administrationProduct AdministrationTime frame: 24 and 72 hours from start time of first study platelet transfusion
    • Editedother outcomeTotal Dose of individual hemostatic adjunctsIndividual Hemostatic Adjuncts (Units/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
    • Editedother outcomeMechanical ventilationVentilationTime frame: up to 28 days after first study platelet transfusion
    • Editedother outcomeLength of stayStayTime frame: up to 28 days
    • Editedother outcomeRelative changeChange in hemostatic parametersHemostatic Parameters at 6 and 24 Hours - HemoglobinTime frame: 6 and 24 hours after first study platelet transfusion
    • Editedother outcomeUnplanned sternal closure delaySternal Closure DelayTime frame: prior to ICU admission
    • Editedother outcomeRe-exploration for bleedingBleedingTime frame: 24 hours first study platelet transfusion
    • Editedother outcomeUnplanned extracorporeal support post operativelyExtracorporeal Support Post OperativelyTime frame: within 48 hours of first study platelet transfusion
    • Editedother outcomeMorbidities afterAfter ICU admissionAdmissionTime frame: within 7 days of first study platelet transfusion
    • Editedother outcomeMeasures of end organ injuryEnd Organ Injury- BUN and CreatinineTime frame: within 48 hours of first study platelet transfusion → within 48 hours of first study platelet transfusion worst value
    • Editedother outcomeTransfusion associated adverse eventsAssociated Adverse EventsTime frame: within 7 days of first study platelet transfusion
    • Editedother outcomeArterial thrombotic eventThrombotic EventTime frame: within 7 days of first study platelet transfusion
    • Editedother outcomeVenous thrombotic eventThrombotic EventTime frame: within 7 days of first study platelet transfusion
    • Editedother outcomeAll cause mortalityCause MortalityTime frame: up to 28 days
    • Addedother outcomeTotal Dose of Individual Hemostatic Adjuncts (mcg/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
    • Addedother outcomeTotal Dose of Individual Hemostatic Adjuncts (mg/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
    • Addedother outcomeTotal Dose of Individual Hemostatic Adjuncts (Grams/kg)Time frame: 24 and 72 hours from start time of first study platelet transfusion
    • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours - HematocritTime frame: 6 and 24 hours after first study platelet transfusion
    • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet CountTime frame: 6 and 24 hours after first study platelet transfusion
    • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- INRTime frame: 6 and 24 hours after first study platelet transfusion
    • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- PTTTime frame: 6 and 24 hours after first study platelet transfusion
    • Addedother outcomeRelative Change in Hemostatic Parameters at 6 and 24 Hours- FibrinogenTime frame: 6 and 24 hours after first study platelet transfusion
    • Addedother outcomeMeasures of End Organ Injury- LactateTime frame: within 48 hours of first study platelet transfusion worst value
    • Addedother outcomeMeasures of End Organ Injury- TroponinTime frame: within 48 hours of first study platelet transfusion.
    • Addedother outcomeMeasures of End Organ Injury- ALT and ASTTime frame: within 48 hours of first study platelet transfusion.
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04834414
Lead sponsor
Philip Spinella
Responsible party
Philip Spinella (Professor- Surgery and Critical Care Medicine, Co- Director- Trauma and Transfusion Medicine Research Center, Associate Medical Director- Center for Military Medicine Research, University of Pittsburgh) — Sponsor-investigator
First posted
Apr 8, 2021
Start date
Oct 21, 2021
Primary completion
Mar 25, 2025
Completion
Apr 21, 2025
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Philip C Spinella, MD
study director · University of Pittsburgh
Marie E Steiner, MD
study director · University of Minnesota
Nicole D Zantek, MD
study director · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion